Clinical trials located in

Sint-Niklaas

Sint-Niklaas city is located in Belgium. Currently, 20 clinical trials are being conducted in this city.

Sint-Niklaas, located in Belgium, is renowned for having the largest market square in the country, spanning 3.19 hectares. This city, established in 1217, is steeped in history and culture. It is also known for its annual balloon festival, attracting hot air balloon enthusiasts from around the globe. Sint-Niklaas is a hub for education and commerce, reflecting a blend of historical charm and modern vitality. The city’s dedication to the arts is evident in its numerous sculptures and murals that adorn the streets, making it a vibrant community in the heart of Belgium.

  • CT-EU-00057564

    Study on new combination therapy for aggressive lymphoma

    This study is about a less common but severe form of cancer known as Diffuse Large B-Cell Lymphoma (DLBCL). It is testing if a new medication called epcoritamab, given with a mix of other commonly used cancer medicines, can help control the disease better. These other medicines include rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone, which are often collectively referred to as R-CHOP. The study includes about 900 adults from around the world who have recently been diagnosed with this type of lymphoma. They will be split into two groups. One group will get epcoritamab with R-CHOP and then continue with epcoritamab. The other group will get R-CHOP followed by rituximab. Doctors will carefully watch for changes in the disease and for any side effects. There will be many checks on health, including medical exams, blood tests, questionnaires, and monitoring of any side effects.

    • Prednisone
    • Vincristine
    • Doxorubicin
    • Epcoritamab
    • Cyclophosphamide
    • Rituximab
  • Evaluating datopotamab deruxtecan & pembrolizumab for advanced lung cancer

    This study compares two treatments for people with a type of lung cancer called ‘non-small cell lung cancer’ that has spread to other parts of the body. It tests whether combining a drug called datopotamab deruxtecan (Dato-DXd) with pembrolizumab works better than using pembrolizumab alone. Aimed at patients with non-small cell lung cancer (NSCLC) who haven’t had previous systemic therapy, it’s especially for those with high PD-L1 tumor expression.

    • Datopotamab deruxtecan
    • Pembrolizumab
  • Comparison study of two melanoma treatments containing pembrolizumab

    This study compares two treatments for a type of skin cancer known as high-risk melanoma. Participants of this study have previously had this cancer surgically removed. The tested treatments are pembrolizumab with vibostolimab, and pembrolizumab alone. The aim is to find out which treatment is better at preventing the melanoma from returning or spreading to other parts of the body. Even after a successful surgery, some cancer cells may be left behind which could result in the cancer returning. The study is measuring the time it takes for the cancer to return and the time it takes for the cancer to spread far from where it started.

    • Vibostolimab
    • Pembrolizumab
  • Comparison of drug combinations in the treatment of advanced lung cancer

    This trial studies a first-line treatment involving Dato-DXd plus pembrolizumab compared to pembrolizumab alone in subjects with advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations. The goal is to evaluate the effectiveness and safety of this combined strategy. Target volunteers must not have received any treatments for their advanced or metastatic NSCLC. Participation includes receiving either the combined treatment or pembrolizumab alone. Regular health checks will monitor if any changes or adverse events occur during the trial.

    • Dato-DXd
    • Pembrolizumab
  • Examining new drug combo vs. standard treatment with pembrolizumab for advanced lung cancer

    This trial is examining if a combination of two medications, Dato-DXd and pembrolizumab, could be superior to using pembrolizumab alone in treating a type of lung cancer known as metastatic non-small cell lung cancer (NSCLC). Participants will include those who have advanced or spread NSCLC and haven’t had systemic treatment for it. The team will be comparing whether the combination treatment can help patients live longer or keep the cancer from growing for a longer period. One group of participants will get pembrolizumab on its own, while another will get both Dato-DXd and pembrolizumab. An important part of the study will assess how the treatment affects the patient’s symptoms and quality of life.

    • Datopotamab deruxtecan
    • Pembrolizumab
  • Testing zamaglutenase for gluten breakdown in celiac disease treatment

    This study focuses on a medicine called zamaglutenase (TAK-062) that may help people with celiac disease. Celiac disease is a condition where the body can’t process gluten, which is found in wheat, rye, and barley. When people with celiac disease eat gluten, their immune system reacts by damaging the small intestine. TAK-062 is meant to break down the gluten in a person’s stomach, possibly helping the body cope better. The study needs around 357 volunteers, who will be split into two groups at random. Both groups will involve adults over 18 years of age. The first group will get a placebo (a medicine-like substance with no actual medicine) and a gluten bar, and the other group will get a dose of TAK-062 alongside the gluten bar. After some time, a committee will check the results of the first group. Depending on what they find, the study may then include teenagers, and the second group will start. Just like any medicine, TAK-062 may or may not cause side effects. Even seemingly unrelated health problems that happen during the study are important, as they could be linked to the medicine, even if it’s not clear at first. This study aims to find clear and truthful results about how TAK-062 works for people with celiac disease.

    • Zamaglutenase/TAK-062
  • Testing personalized treatments for advanced prostate cancer

    ProBio is a worldwide study for patients with advanced prostate cancer. It will look at whether new treatments can help patients based on their unique cancer characteristics. Patients are allocated in two groups: one will receive usual care following local guidelines (control group). The other group will be given treatments designed specifically for their type of cancer. These treatments will be chosen based on their cancer’s unique characteristics – what is called ‘biomarker signatures’. Depending on how well they respond to the treatment, patients may be moved to different treatments. Each treatment will be compared to standard care for effectiveness. The researchers will decide if treatments are effective, should continue, or should be stopped. New types and combinations of treatments can be included in the future. The study will use well-established standards to assess cancer improvement. Quality of life and costs of the treatment will also be evaluated. Side effects and responses to treatment at 6 months will also be recorded.

    • Abiraterone
    • Cabazitaxel
    • Radium Chloride Ra-223
    • enzalutamide
    • Apalutamide
    • Niraparib
    • Darolutamide
    • Capivasertib
    • Prednisone
    • Carboplatin
    • Docetaxel
  • Studying the safety and effectiveness of a new drug for ulcerative colitis

    This study focuses on examining a drug called ABBV-668, administered in oral capsules, to evaluate its safety and effectiveness in the treatment of adults with ulcerative colitis, a gastrointestinal disease characterized by bleeding and inflammation in the large intestine. About 40 participants will take the capsules twice a day for 16 weeks. After this treatment period, doctors will continue to monitor participants for an additional month. The study involves visiting a doctor more often than usual, carefully checking for potential side effects, and asking participants-specific questions. To measure changes in participants’ condition, doctors will use a special scoring system.

    • ABBV-668- new potential medication for inflammatory bowel diseases
  • Comparing tarlatamab and standard therapy in recurring small cell lung cancer

    The study is a trial comparing tarlatamab, a new therapy, with standard care for Small Cell Lung Cancer (SCLC) patients who’ve had platinum-based chemotherapy. It aims to improve survival rates and assesses the drug’s safety and effectiveness in about 700 people. Participants will either receive tarlatamab or standard treatments like lurbinectedin, topotecan, or amrubicin. The main goal is to see if tarlatamab can extend patients’ lives compared to usual treatments. The study also monitors health-related quality of life, treatment response, and safety.

    • Amrubicin
    • Tarlatamab
    • topotecan
    • Lurbinectedin
  • Testing navitoclax and ruxolitinib effective on myelofibrosis patients

    This study is trying to find out if the combination of two drugs called Navitoclax and Ruxolitinib can help people with a type of blood cancer called Myelofibrosis. Around 330 adults, who have myelofibrosis that hasn’t responded to previous treatments, will get either the new drug combination or the current best treatment for their disease. Doctors will measure whether the new combination is more effective by checking how much the size of participants’ spleens have changed during the study with scans, measuring fatigue levels and checking how well their bone marrow works.

    • Navitoclax
    • Ruxolitinib
  • Study on a new combination therapy for active ulcerative colitis

    This study aims to assess the effectiveness and safety of new combination therapy with JNJ-78934804 (Guselkumab/Golimumab) in comparison to guselkumab and golimumab administred alone for individuals with moderately to severely active ulcerative colitis. Participants who have shown inadequate response, loss of response, or intolerance to approved advanced therapies will be included. The trial includes various treatment groups: placebo, Guselkumab, Golimumab, and different doses of JNJ-78934804. All participants meeting inadequate response criteria will be escalated to an active treatment. The study will last for 48 weeks and the progress will be tracked over this period. The primary focus is to evaluate the efficacy and safety of the different doses of new therapy in managing ulcerative colitis over the course of the study.

    • JNJ-78934804/guselkumab + golimumab
    • Golimumab
    • Guselkumab
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • A study of lanifibranor treatment in adults with nonalcoholic fatty liver disease

    This study is a two-part trial looking at how well a drug called Lanifibranor works for adults suffering from liver diseases known as NASH and fibrosis stages F2 and F3. In the first part of the trial, the researchers will compare the effects of Lanifibranor with a placebo, which is a substance with no medical effect. The researchers will be looking at how much the drug can improve the health of the liver. The second part of the study will continue the use of Lanifibranor to see if there are any long-term safety issues. Apart from studying the drug’s effectiveness in resolving NASH and reducing live fibrosis, the trial will also be observing how it affects other aspects of liver health, diabetes, blood sugar and fat levels, liver stiffness and patients’ quality of life.

    • Lanifibranor
  • Combination therapy trial for moderately to severely active Crohn’s disease

    The study examines a combination therapy using guselkumab and golimumab in individuals with active Crohn’s Disease. It aims to compare the effectiveness of this dual approach to individual treatments, focusing on reducing disease symptoms and improving patients’ quality of life. The study’s goal is to offer new hope and better management strategies for those battling this challenging condition.

    • JNJ-78934804 (guselkumab, golimumab)
    • Golimumab
    • Guselkumab
  • CT-EU-00036742

    Monitoring RSV vaccine safety in post-vaccination pregnancies

    This study tracks the safety of the RSVPreF3 vaccine in women who had it during previous pregnancies. It’s focused on women who are pregnant again after receiving the vaccine and will assess the health of both mothers and their babies. The study’s main aim is to understand any potential impacts of the vaccine on pregnancy outcomes and infant health. This research is important as it provides vital information on the safety of RSV vaccines in pregnant women, contributing to public health knowledge.

  • Study of new combined therapy for untreatable lung membrane cancer

    This study is testing a new treatment for pleural mesothelioma, a type of lung cancer. It compares a new drug, Volrustomig combined with carboplatin and pemetrexed, against drugs chosen by the researcher, which could include platinum, pemetrexed, nivolumab, or ipilimumab. The goal is to see which treatment works better and is safer. About 600 adults with advanced mesothelioma that can’t be removed by surgery will participate. The study will look at how long patients live with each treatment and other health factors.

    • Volrustomig
    • Nivolumab
    • Ipilimumab
    • Pemetrexed
    • Cisplatin
    • Carboplatin
  • Study of Dato-DXd and durvalumab in persistent triple-negative breast cancer

    This trial is about testing a combination of new treatments for triple-negative breast cancer which hasn’t fully responded to the first line of treatment. The new treatment includes a drug called Dato-DXd and a known drug called Durvalumab, both administered individually, or as a combination. This is compared to an already established treatment recommended by the doctor. The researchers are mainly interested in delaying the return of the cancer, and if the new drug with or without Durvalumab does a better job at this than the doctor-recommended treatment. Along with this main goal, the trial will also monitor how these treatments affect patients’ routine activities, their well-being, their levels of fatigue, the amount of Dato-DXd and related components present in the body, and any side effects and potential risks associated with these treatments.

    • Dato-DXd
    • Pembrolizumab
    • Capecitabine
    • Durvalumab
  • Radiation and durvalumab study for early lung cancer patients

    This is a study examining the effectiveness and safety of duvalumab added to high-power radiotherapy to fight stage I or II lung cancer that has not spread to the lymph nodes. Researchers will randomly divide participants into two equal groups. One group will receive Durvalumab, the other – placebo. Both groups will receive the same radiotherapy. The aim is to see if Durvalumab helps people live longer and prevents the cancer from developing again. They also have a separate group who have a specific cancer gene mutation and who will receive osimertinib after radiation therapy. For this group of patients, specialists want to determine whether osimertinib can prevent cancer recurrence for up to four years.

    • Osimertinib
    • Durvalumab
  • Dato-DXd versus Standard Chemotherapy in Advanced Triple-negative Breast Cancer Study

    This clinical trial investigates a new treatment, Dato-DXd, compared to standard chemotherapy for patients with triple-negative breast cancer that is locally recurrent, inoperable, or metastatic and not suitable for PD-1/PD-L1 inhibitor therapy. The study, open to adults, aims to assess the treatment’s effectiveness and safety through random assignment to either Dato-DXd or investigator-chosen chemotherapy. The trial seeks 600 participants and involves regular monitoring of health and progression of the disease. It emphasizes patient eligibility based on specific health criteria and the nature of their breast cancer.

    • Eribulin mesylate
    • Dato-DXd
    • Carboplatin
    • nab-Paclitaxel
    • Capecitabine
    • Paclitaxel

See more clinical trials in other cities in Belgium:

.